FDA delays decision on Dupixent in COPD; Summit makes a bold claim
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a line! Today, a brief rundown of news from Regeneron, Summit Therapeutics and Verve …